Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2026 21:30 ET | Source: Milestone Pharmaceuticals Inc. MONTREAL and…
Jelly Force Male Enhancement Gummies Release Latest Formula for Men: JellyForce Unique Ingredient Profile Report
Pinellas Park, FL, July 02, 2026 (GLOBE NEWSWIRE) -- These statements have…
Seer Announces Receipt of Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.
No Stockholder Action Required at This Time July 02, 2026 17:00 ET…
Chinese inventors Xie Yinghao and Yu Haijun secure dual win at the European Inventor Award 2026 for smart battery recycling
Xie Yinghao, Yu Haijun and their team receive the European Inventor Award…
Herb Meiner’s Rock It Like Herb Unveils a New Episode on Leadership, Innovation, and Transparency
Bali, Indonesia, July 02, 2026 (GLOBE NEWSWIRE) -- Herb Meiner has released the…
Alarum Technologies Responds to Inquiry into Residential Proxy Networks
July 02, 2026 17:42 ET | Source: Alarum Technologies Ltd. Tel Aviv,…
Abivax Announces Full Exercise of Underwriters Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (807M)
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing…
DXS INTERNATIONAL PLC (AQSE: DXSP): Trading Update
The information communicated within this announcement is deemed to constitute inside information…
![[Ad hoc announcement pursuant to Art. 53 LR] Roches divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer](https://i0.wp.com/ml-eu.globenewswire.com/Resource/Download/696b7c85-2d23-4f5e-a77b-8c6b2fa45d47?w=420&resize=420,280&ssl=1 "[Ad hoc announcement pursuant to Art. 53 LR] Roches divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer")
[Ad hoc announcement pursuant to Art. 53 LR] Roches divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer
Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated…
Jet.AI Stockholder Votes Exceed Majority Threshold for flyExclusive Transaction
Holders of Record as of July 6th Eligible for Merger Consideration Pending…
